Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Is TTF-1 a prognostic marker in non-small cell lung adenokarsinoma?

Murat Araz, Hacer Demir, Ismail Beypinar.




Abstract

Thyroid transcription factor-1 (TTF-1) is first found to be a promoter of the thyroglobulin. The primary function of this protein is the regulation of nuclear transcription.TTF-1 has suggested having both oncogenic and anti-oncogenic effects on tumor biology. A total number of 1104 patient’s data with lung cancers are evaluated. When the patients without adenocarcinoma histology, unknown TTF-1 status, and lost follow-up were excluded, the remaining total number of 104 patient’s characteristics, chemotherapy types, treatment responses (as accommodation with Response Evaluation Criteria in Solid Tumors), progression-free survival (PFS) and overall survival (OS) were recorded and analyzed.TTF-1 positivity is significantly correlated with the female gender. The biopsy location among the groups was statistically different between the TTF-1 positive and negative groups. The EGFR mutation rate was significantly higher in the TTF-1 positive group. In the survival analysis, the TTF-1 positive patients have a significantly better OS in all study population. The statistically significant survival advantage was going on in the TTF-1 positive group when the TKI treated patients excluded. The PFS was not significantly different between the two groups. However, when the TKI treated patients excluded in both groups; the TTF-1 positive group had a significantly better PFS. In conclusion, TTF-1 positivity may be used as a positive prognostic marker for lung adenocarcinoma independent from TKI usage because of strongly correlated with a better OS.

Key words: Lung adenocarcinoma, Prognostic marker, TTF-1






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.